Expression of CD25, CD122, and CD132 in the 3 groups of participants
| Cell type/chain . | Participant group . | P . | ||||
|---|---|---|---|---|---|---|
| HIV− (n = 16) . | HAART (n = 16) . | IL-2 + HAART (n = 16) . | HIV−vs HAART . | HIV− vs IL-2 + HAART . | HAART vs IL-2 + HAART . | |
| CD4+ T cells | ||||||
| CD25 (%) | 28.3 (17.3-45.8) | 23 (11.1-48.8) | 53.6 (23.0-69.8) | NS | < .001 | < .001 |
| CD25 (MFI) | 28.0 (23.0-36.8) | 28 (23.1-40.8) | 41.3 (27.9-68.5) | NS | < .001 | < .001 |
| CD122 (%) | 1.8 (1.4-7.0) | 1.8 (0.7-3.6) | 1.2 (0.3-4.3) | NS | .02 | NS |
| CD122 (MFI) | 2.6 (1.7-3.9) | 2.9 (2.1-4.2) | 2.7 (2.0-3.7) | NS | NS | NS |
| CD132 (MFI; n = 7) | 4.4 (3.3-7.9) | 7.4 (5.0-9.7) | 4.6 (3.2-5.6) | NS | NS | .01 |
| CD8+ T cells | ||||||
| CD25 (%) | 3 (1.2-7.3) | 1.2 (0.5-7.4) | 5.9 (1.6-45.9) | NS | .01 | .01 |
| CD25 (MFI) | 21.8 (18.5-25.7) | 21.8 (18.7-36.3) | 28.5 (21.0-42.5) | NS | .02 | .02 |
| CD122 (%) | 13.1 (5.2-33.6) | 16.4 (5.3-59.5) | 14.6 (2.2-34.5) | NS | NS | NS |
| CD122 (MFI) | 4.6 (2.9-8.4) | 6.0 (4.2-13.7) | 6.0 (3.8-11.9) | .03 | .03 | NS |
| CD132 (MFI; n = 7) | 4.9 (3.9-8.5) | 7.6 (5.5-13.9) | 6.6 (4.4-7.6) | NS | NS | NS |
| NK cells | ||||||
| CD25 (%) | 1.9 (0.7-4.3) | 2.4 (0.9-6.0) | 2.1 (0.4-6.2) | NS | NS | NS |
| CD122 (%) | 94.3 (27.7-97.8) | 93.4 (80.2-96.9) | 93.6 (49.0-97.6) | NS | NS | NS |
| Cell type/chain . | Participant group . | P . | ||||
|---|---|---|---|---|---|---|
| HIV− (n = 16) . | HAART (n = 16) . | IL-2 + HAART (n = 16) . | HIV−vs HAART . | HIV− vs IL-2 + HAART . | HAART vs IL-2 + HAART . | |
| CD4+ T cells | ||||||
| CD25 (%) | 28.3 (17.3-45.8) | 23 (11.1-48.8) | 53.6 (23.0-69.8) | NS | < .001 | < .001 |
| CD25 (MFI) | 28.0 (23.0-36.8) | 28 (23.1-40.8) | 41.3 (27.9-68.5) | NS | < .001 | < .001 |
| CD122 (%) | 1.8 (1.4-7.0) | 1.8 (0.7-3.6) | 1.2 (0.3-4.3) | NS | .02 | NS |
| CD122 (MFI) | 2.6 (1.7-3.9) | 2.9 (2.1-4.2) | 2.7 (2.0-3.7) | NS | NS | NS |
| CD132 (MFI; n = 7) | 4.4 (3.3-7.9) | 7.4 (5.0-9.7) | 4.6 (3.2-5.6) | NS | NS | .01 |
| CD8+ T cells | ||||||
| CD25 (%) | 3 (1.2-7.3) | 1.2 (0.5-7.4) | 5.9 (1.6-45.9) | NS | .01 | .01 |
| CD25 (MFI) | 21.8 (18.5-25.7) | 21.8 (18.7-36.3) | 28.5 (21.0-42.5) | NS | .02 | .02 |
| CD122 (%) | 13.1 (5.2-33.6) | 16.4 (5.3-59.5) | 14.6 (2.2-34.5) | NS | NS | NS |
| CD122 (MFI) | 4.6 (2.9-8.4) | 6.0 (4.2-13.7) | 6.0 (3.8-11.9) | .03 | .03 | NS |
| CD132 (MFI; n = 7) | 4.9 (3.9-8.5) | 7.6 (5.5-13.9) | 6.6 (4.4-7.6) | NS | NS | NS |
| NK cells | ||||||
| CD25 (%) | 1.9 (0.7-4.3) | 2.4 (0.9-6.0) | 2.1 (0.4-6.2) | NS | NS | NS |
| CD122 (%) | 94.3 (27.7-97.8) | 93.4 (80.2-96.9) | 93.6 (49.0-97.6) | NS | NS | NS |
Values are medians (range).
NS indicates nonsignificant (higher than or equal to .05); comparisons were higher than or equal to P = .1 in all instances.